(MENAFN- EIN Presswire)
Pneumococcal Vaccine Market
Pneumococcal Vaccine market Forecast to Surge to US$ 14.43 Billion by 2032, Achieving a Remarkable 6.4% CAGR
Government-subsidized immunization programs are pushing the market forward” - Polaris Market ResearchNEW YORK CITY, NY, UNITED STATES, January 10, 2025 /EINPresswire / -- The pneumococcal vaccine market forecast for 2032 is a specialized study of the
industry with a specific concentration on the global market trend analysis.
According to an exhaustive report by Polaris Market Research, the global pneumococcal vaccine market is poised for significant growth over the next decade. In 2023, global sales income reached USD 8.27 billion. Predicted to boost at a robust CAGR of 6.4%, the market is estimated to reach USD 14.43 billion by 2032.
What is Pneumococcal Vaccine?
Pneumococcal illness is normal in young children, but grownups have a substantial probability of grave illness and death. Pneumococcal vaccines assist safeguard against pneumococcal infections involving invasive illness. Invasive illness indicates that bacteria occupy components of the body, such as blood, that are usually liberated from germs.
Download Free Sample PDF Copy of the Report:
/request-for-sample?utm_source=Ein&utm_medium=Ein&utm_campaign=Ein&utm_id=01
CDC endorses pneumococcal vaccination for persons dependent on their age or if they possess specific probability conditions. Pneumococcal vaccines are the foremost method to safeguard against grave pneumococcal contamination. Government initiatives highlight the growing global allegiance to confronting pneumococcal contaminations, impacting the pneumococcal vaccine market growth favorably.
Who Makes Pneumococcal Vaccine?
.GSK plc
.Pfizer Inc.
.Merck KGaA
.Serum Institute of India Pvt. Ltd.
.CSL Ltd.
.Sanofi S.A.
.Walvax Biotechnology Co., Ltd.
.Beijing Minhai Biotechnology Co., Ltd
.Johnson & Johnson
.AstraZeneca
.Novavax
are some of the leading players in the pneumococcal vaccine market.
The market is splintered. The growing funding in R&D for pneumococcal vaccines and contemporary technology influence the global market. Some of the latest developments in the market are:
.In April 2024, Merck declared outcomes from the STRIDE-10 Phase 3 trial of its exploratory V116 pneumococcal vaccine at the ESCMID Global conference in Barcelona. V116, a 21-valent vaccine, exhibited superlative immune reactions, as contrasted to PPSV23 for allocated serotypes and better outcomes for extra serotypes.
.In December 2023, Sinovac Life Science declared clinical attempts for the Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) that involves 13 serotypes amidst children of age classification 2-23 months and 3-60 months.
What's Driving Market Forward?
Effective Vaccine Distribution: The expression of several associations for vaccine dissemination is anticipated to escalate the demand for pneumococcal vaccines worldwide, causing market growth. For instance, in 2022, GAVI registered that the scope of the third dose of the pneumococcal conjugate vaccine (PCV3) surged to 70%, up from 56% in 2019-2021.
Growing Cases of Pneumococcal Illnesses: The rising cases of pneumococcal illnesses covering all age categories are driving the market ahead. Growing cases of contamination involving grave conditions such as pneumonia, meningitis, and bacteremia are pushing the demand for productive, prohibitive measures. This, in turn, is having a favorable impact on pneumococcal vaccine market sales.
Rising Favourable Government Policies: The market is foremost propelled by government advantages and health strategies that encourage extensive vaccination. Strategies involve embracing pneumococcal vaccines into pattern immunization programs and approving them for high-probability categories such as grown-ups and young children.
Request for a Discount on this Report Before Purchase:
/request-for-discount-pricing?utm_source=Ein&utm_medium=Ein&utm_campaign=Ein&utm_id=01
Which Region Leads Market Growth?
North America: North America accounted for the largest pneumococcal vaccine market share. The region's robust growth is primarily due to a robust healthcare framework and an escalating aggregate of FDA consent.
Asia Pacific: Asia Pacific is anticipated to witness significant growth from 2024 to 2032. This can be attributed to growing funding for vaccine advancement and a speedily burgeoning population.
How Is Market Segmentation Done?
By Vaccine Type Outlook
.Pneumococcal conjugate vaccine
.Pneumococcal polysaccharide vaccine
By Product Outlook
.Prevnar 13
.Synflorix
.Pneumovax23
.Others
By End User Outlook
.Public Sector
.Private Sector
By Regional Outlook
.North America
oUS
oCanada
.Europe
oGermany
oFrance
oUK
oItaly
oSpain
oNetherlands
oRussia
oRest of Europe
.Asia Pacific
oChina
oJapan
oIndia
oMalaysia
oSouth Korea
oIndonesia
oAustralia
oRest of Asia Pacific
.Middle East & Africa
oSaudi Arabia
oUAE
oIsrael
oSouth Africa
oRest of the Middle East & Africa
.Latin America
oMexico
oBrazil
oArgentina
oRest of Latin America
Inquire more about this Report Before Purchase:
/inquire-before-buying?utm_source=Ein&utm_medium=Ein&utm_campaign=Ein&utm_id=01
FAQs:
How much is the pneumococcal vaccine market?
The market size was valued at USD 8.27 billion in 2023 and is projected to grow to USD 14.43 billion by 2032.
Which region held the highest share in the pneumococcal vaccine market?
North America held the largest share.
Which segment by type analysis had the highest revenue share in the market?
The pneumococcal polysaccharide vaccine (PPV) segment had the largest revenue share in the market.
What is the growth rate of the market?
The global market is projected to grow at a CAGR of 6.4% during the forecast period, 2024-2032.
Browse More Research Reports:
Amyloidosis Treatment Market:
Spatial Proteomics Market:
In Vitro Diagnostics Quality Control Market:
GLP-1 Analogues Market:
Idiopathic Pulmonary Fibrosis Treatment Market:
About Polaris Market Research & Consulting, Inc:
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.
Likhil G
Polaris Market Research and Consulting
+1 929-297-9727
...
Visit us on social media:
Facebook
X
LinkedIn
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
MENAFN10012025003118003196ID1109076579